Frühansprechen auf Antidepressiva: die prognostische Bedeutung der Probetherapie

  • B. Woggon
Conference paper
Part of the Tropon-Symposium book series (BAYERZNS, volume 5)

Zusammenfassung

Etwa ein Drittel der medikamentös behandelten depressiven Patienten spricht auf das erstverordnete Antidepressivum nicht an. Noch ungünstiger sieht es bei hospitalisierten depressiven Patienten aus: Von diesen zeigt nur etwa die Hälfte eine Besserung (Woggon 1979). Spricht ein Patient auf die erste antidepressive Behandlung nicht an, so sollte dies nicht als Therapieresistenz bezeichnet werden. Es ist zwar bisher nicht gelungen eine einheitliche Definition des Begriffes „Therapieresistenz“ herauszuarbeiten, am häufigsten wird aber folgende verwendet: Nichtansprechen auf zwei verschiedene Antidepressiva in adäquater Dosierung (entsprechend ≥150 mg Imipramin/Tag) und von adäquater Behandlungsdauer (≥4 Wochen).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Amsterdam JD, Berwish NJ (1989) High dose Tanylcypromine therapy for refractory depression. Pharmacopsychiatry 22:21–25PubMedCrossRefGoogle Scholar
  2. Angst J, Beck P, Boyer P, Bruinvels J, Engel H, Heimchen H, Hippius H, Lingjaerde O, Racagni G, Saletu B, Sedvall G, Silverstone JT, Stefanis CN, Stoll K, Woggon B (1989) Consensus conference on the methodology of clinical trials of antidepressants, Zurich, March 1988: Report of the Consensus Committee. Pharmacopsychiatry 22:3–7CrossRefGoogle Scholar
  3. Bridges PK (1983) ”... And a small dose of an antidepressant might help”. Br J Psychiatry 142:626–628PubMedCrossRefGoogle Scholar
  4. Ceroni GB, Neri C, Pezzoli A (1984) Chronicity in major depression - a naturalistic prospective study. J Affect Dis 7:123–132CrossRefGoogle Scholar
  5. Chan CH, Janicak PG, Davis JM, Altman E, Andriukaitis S, Hedeker D (1987) Response of psychotic and nonpsychotic depressed patients to tricyclic antidepressants. J Clin Psychiatry 48:197–200PubMedGoogle Scholar
  6. Fähndrich E, Haug HJ (1987) Die wahnhafte Depression - ein eigenständiges Krankheitsbild? In: 15. AGNP-Symposium Nürnberg, Abstracts, p 81ffGoogle Scholar
  7. Fairchild CJ, Rush AJ, Vasavada N, Giles DE, Khatami M (1986) Which depressions respond to placebo. Psychiatry Res 18:217–226PubMedCrossRefGoogle Scholar
  8. Garvey MJ, Tollefson GD, Tuason VB (1986) Is chronic primary major depression a distinct depression subtype? Compr Psychiatry 27:446–448PubMedCrossRefGoogle Scholar
  9. Guze BH, Baxter LR, Rego J (1987) Refractory depression treated with high doses of a monoamine oxidase inhibitor. J Clin Psychiatry 48:31–32PubMedGoogle Scholar
  10. Haskel DS, DiMascio A, Prusoff B (1975) Rapidity of symptom reduction in depressions treated with Amitriptyline. J Nerv Ment Dis 160:24–33CrossRefGoogle Scholar
  11. Hordern A, Holt NF, Burt CG, Gordon WF (1963) Amitriptyline in depressive states. Phenomenology and prognostic considerations. Br J Psychiatry 109:815–825PubMedCrossRefGoogle Scholar
  12. Johnson DAW (1981) Depression: treatment compliance in general practice. Acta Psychiatr Scand [Suppl 290] 63:447–453CrossRefGoogle Scholar
  13. Katz MM, Koslow SH, Maas JW, Frazer A, Bowden CL, Casper R, Croughan J, Kocsis J, Redmond JRE (1987) The toming, specificity and clinical prediction of tricyclic drug effects in depression. Psychol Med 17:297–309PubMedCrossRefGoogle Scholar
  14. Keller MB, Klerman GL, Lavori PW, Fawcett JA, Coryell W, Endicott J (1982) Treatment received by depressed patients. JAMA 248:1848–1855PubMedCrossRefGoogle Scholar
  15. Keller MB, Lavori PW, Rice J, Coryell W, Hirschfeld RMA (1986) The persistent risk of chronicity in recurrent episodes of nonbipolar major depressive disorder: A prospective follow-up. Am J Psychiatry 143:24–28PubMedGoogle Scholar
  16. Kotin J, Post RM, Goodwin FK (1973) Drug treatment of depressed patients referred for hospitalization. Am J Psychiatry 130:1139–1141PubMedGoogle Scholar
  17. Kuhn R (1957) Über die Behandlung depressiver Zustände mit einem Iminodibenzylderivat (G 22355). Schweiz Med Wochenschr 87:1135–1140PubMedGoogle Scholar
  18. Kupfer DJ, Frank E, Perel JM (1989) The advantage of early treatment intervention in recurrent depression. Arch Gen Psychiatry 46:771–775PubMedCrossRefGoogle Scholar
  19. Lesse S (1960) The evaluation of imipramine hydrochloride in the ambulatory treatment of depressed patients. J Neuropsychiatr 1:246–252PubMedGoogle Scholar
  20. Liebowitz MR, Quitkin FM, Stewart JW, McGrath PJ, Harrison WM, Markowitz JS, Rabkin JG, Tricamo E, Goetz DM, Klein DF (1988) Antidepressant specificity in atypical depression. Arch Gen Psychiatry 45:129–137PubMedCrossRefGoogle Scholar
  21. Michel K (1986) Suizide und Suizideversuche: Könnte der Arzt mehr tun? Schweiz Med Wochenschr 116:770–774PubMedGoogle Scholar
  22. Modestin J (1985) Antidepressive therapy in depressed clinical suicides. Acta Psychiatr Scand 71:111–116PubMedCrossRefGoogle Scholar
  23. Möller HJ, Fischer G, Zerssen D v (1987) Prediction of therapeutic response in acute treatment with antidepressants. Eur Arch Psychiatr Neurol Sci 236:349–357CrossRefGoogle Scholar
  24. Nelson JC, Mazure C, Quinlan DM, Jatlow PI (1984) Drug-responsive symptoms in melancholia. Arch Gen Psychiatry 41:663–668PubMedCrossRefGoogle Scholar
  25. Nies A (1984) Differential response patterns to MAO inhibitors and tricyclics. J Clin Psychiatry 45:70–77PubMedGoogle Scholar
  26. Overholser JC, Miller IW, Norman WH (1987) The course of depressive symptoms in suicidal vs. non- suicidal depressed inpatients. J Nerv Ment Dis 175:450–456PubMedCrossRefGoogle Scholar
  27. Paykel ES, Hollyman JA, Freeling P, Sedgwick P (1988) Predictors of therapeutic benefit from amitriptyline in mild depression: a general practice placebo-controlled trial. J Affect Dis 14:83–95PubMedCrossRefGoogle Scholar
  28. Paykel S, Prusoff BA (1973) Response set and observer set in the assessment of depressed patients. Psychol Med 3:209–216PubMedCrossRefGoogle Scholar
  29. Quitkin FM (1985) The importance of dosage in prescribing antidepressants. Br J Psychiatry 147:593–597PubMedCrossRefGoogle Scholar
  30. Quitkin FM, Stewart JW, McGrath PJ, Liebowitz MR, Harrison WM, Tricamo E, Klein DF, Rabkin JG, Markowitz JS, Wagner SG (1988) Phenelzine versus Imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders. Am J Psychiatry 145:306–311PubMedGoogle Scholar
  31. Quitkin FM, McGrath PJ, Stewart JW, Harrison W, Wagner SG, Nunes E, Rabkin JG, Tricamo E, Markowitz J, Klein DF (1989) Phenelzine and Imipramine in mood reactive depressives. Arch Gen Psychiatry 46:787–793PubMedCrossRefGoogle Scholar
  32. Remick RA (1989) Treatment resistant depression. Psychiatric J Univ Ottawa 14:394–396Google Scholar
  33. Rose JT, Westhead TT (1967) Treatment of depression. A comparative trial of Imipramine and Desipramine. Br J Psychiatry 113:659–665PubMedCrossRefGoogle Scholar
  34. Rush AJ, Hiser W, Giles DE (1987) A comparison of self-reported versus clinician-rated symptoms in depression. J Clin Psychiatry 48:246–248PubMedGoogle Scholar
  35. Schatzberg AF, Cole JO, Cohen BM, Altesman RI, Sniffin CM (1983) Survey of depressed patients who have failed to respond to treatment. In: Davis JM, Maas JW (eds) The affective disorders. Am Psychiatr Press Inc, Washington DC, pp 73–86Google Scholar
  36. Schuckit MA, Feighner JP (1972) Safety of High-Dose Tricyclic Antidepressant Therapy. Am J Psychiatry 128:1456–1459PubMedGoogle Scholar
  37. Small JG, Milstein V, Kellams JJ, Small IF (1981) Comparative onset of improvement in depressive symptomatology with drug treatment, electroconvulsive therapy, and placebo. J Clin Psychopharmacol 1/6 [Suppl]:62S-69SCrossRefGoogle Scholar
  38. Spear FG, Hall P, Stirland JD (1964) A comparison of subjective responses to Imipramine and Tranylcypromine. Br J Psychiatry 110:53–55PubMedCrossRefGoogle Scholar
  39. Waldron J, Bates TJN (1965) The management of depression in hospital. A comparative trial of Desi- pramine and Imipramine. Br J Psychiatry 111:511–516PubMedCrossRefGoogle Scholar
  40. Wittenborn JR, Kiremitci N (1975) A comparison of antidepressant medications in neurotic and psychotic patients. Arch Gen Psychiatry 32:1172–1176PubMedCrossRefGoogle Scholar
  41. Woggon B (1979) Klinische Psychopharmakologie. In: Psychiatrische Universitätsklinik Zürich, Forschungsdirektion. Zehnjahresbericht 1969–1979, Zürich, pp 67–105Google Scholar
  42. Woggon B (1980) Veränderungen der psychopathologischen Symptomatik während 20-tägiger antidepressiver oder neuroleptischer Behandlung. Psychiatr Clin 13:150–164Google Scholar
  43. Woggon B (1983) Prognose der Psychopharmakotherapie. Enke, StuttgartGoogle Scholar
  44. Woggon B, Angst J (1980) Psychopharmakotherapie. In: Kisker KP, Meyer JE, Müller C, Strömgren E (Hrsg) Psychiatrie der Gegenwart, Forschung und Praxis. Grundlagen und Methoden der Psychiatrie, Band I, 2 Aufl, Teil 2. Springer, Berlin Heidelberg New York Tokyo, pp 243–314Google Scholar
  45. Woggon B, Bosshart P, Meyer JW, Baumann P (1988) Mögliche Konsequenzen des Debrisoquin-Hy- droxylierungsdefektes für die Behandlung mit Psychopharmaka - Zusammenfassung mehrerer Schweizer Untersuchungen. In: Gross G, Huber G (Hrsg) Das ärztliche Gespräch, Band 44: Neuere pharmakopsychiatrische und neurochemische Ergebnisse der Psychosenforschung. 3. Hans Jörg Weitbrecht-Symposion, 20.02.1988, Bonn, Troponwerke, Köln, pp 79–86Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • B. Woggon

There are no affiliations available

Personalised recommendations